Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer

International Journal of Oncology

Volumn 30, Issue 2, 2007, Pages 509-520

  Osipo, Clodia ^a,b   Meeke, Kathleen ^b   Cheng, Dong ^b   Weichel, Alyssa ^b   Bertucci, Anne ^b   Liu, Hong ^b   Jordan, V Craig ^b,c  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

Breast cancer; Fulvestrant; HER2 neu; HER3

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MONOCLONAL ANTIBODY; PERTUZUMAB; TAMOXIFEN;

ANIMAL; ARTICLE; BREAST TUMOR; CANCER TRANSPLANTATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PHOSPHORYLATION; PHYSIOLOGY; PROTO ONCOGENE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 34047274789     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609-1618, 1998.
2. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388, 1998.
3. Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, et al: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 4: 459-471, 1986. (Pubitemid 16117934)
4. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, et al: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 14: 2000-2011, 1996.
5. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453-461, 1998.
6. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606, 2001.
7. Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P, Cooper B, et al: Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol 17: 3418-3425, 1999.
8. Bundred N and Howell A: Fulvestrant (Faslodex): current status in the therapy of breast cancer. Expert Rev Anticancer Ther 2: 151-160, 2002. (Pubitemid 34679470)
9. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, et al: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20: 3386-3395, 2002.
10. Miller WR, Hawkins RA and Forrest AP: Significance of aromatase activity in human breast cancer. Cancer Res 42 (Suppl 8): 3365-3368, 1982.
11. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, et al: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22: 1605-1613, 2004.
12. Wijayaratne AL and McDonnell DP: The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 276: 35684-35692, 2001. (Pubitemid 33652619)
13. Hong LE-SL, Gajdos C, Pearce ST, Chen B, Osipo C, Loweth J, McKian K, De Los Reyes A, Wing L and Jordan VC: Apoptotic action of 17beta-estradiol in raloxifene resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 95: 1586-1597, 2003.
14. Franco S, Perez A, Tan-Chiu E, Frankel C and Vogel CL: Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience. Breast Cancer Res Treat 88: 103-108, 2004.
15. Steger GG, Gips M, Simon SD, Lluch A, Vinholes J, Kaufman B, et al: Fulvestrant ('Faslodex'): clinical experience from the Compassionate Use Programme. Cancer Treat Rev 31 (Suppl 2): 10-16, 2005.
16. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, et al: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95: 353-361, 2003.
17. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, et al: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926-935, 2004.
18. Robinson SP and Jordan VC: Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 49: 1758-1762, 1989.
19. O'Regan RM, Cisneros A, England GM, MacGregor JI, Muenzner HD, Assikis VJ, et al: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 90: 1552-1558, 1998.
20. Gottardis MM and Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after longterm antiestrogen administration. Cancer Res 48: 5183-5187, 1988.
21. Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM, et al: Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6: 2028-2036, 2000. (Pubitemid 30305102)
22. Dubik D and Shiu RP: Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7: 1587-1594, 1992.
23. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, et al: Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 269: 16433-16442, 1994. (Pubitemid 24209344)
24. Augereau P, Miralles F, Cavailles V, Gaudelet C, Parker M and Rochefort H: Characterization of the proximal estrogen-responsive element of human cathepsin D gene. Mol Endocrinol 8: 693-703, 1994.
25. Brown AM, Jeltsch JM, Roberts M and Chambon P: Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci USA 81: 6344-6348, 1984.
26. Osborne CK and Schiff R: Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 12: 362-367, 2003.
27. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005.
28. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, et al: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24: 85-95, 1993. (Pubitemid 23063891)
29. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, et al: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446, 1995.
30. Kurokawa H and Arteaga CL: Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 7 (Suppl 12): S4436-S4442, 2001.
31. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, et al: Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142: 2776-2788, 2001.
32. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, et al: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044, 2003.
33. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, et al: Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 8: 175-182, 2001. (Pubitemid 32947639)
34. Osipo C, Gajdos C, Liu H, Chen B and Jordan VC: Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 95: 1597-608, 2003.
35. Osipo C, Gajdos C, Cheng D and Jordan VC: Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol 93: 249-256, 2005.
36. Ingle JNSV, Mirchandani D, Bernath AM, Camoriano JK and Perez EA: Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group. Breast Cancer Res Treat (Suppl) 88: 38, 2004.
37. Perey LPRNF, Bonnefoi H, Aebi S, Goldhirsch A, Dietrich D and Thurlimann D, for the Swiss Group for Clinical Cancer Research (SAKK): Fulvestrant (Faslodex) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: update of a phase II SAKK trial. Breast Cancer Res Treat (Suppl) 88: 236, 2004.
38. Torres-Arzayus MI, De Mora JF, Yuan J, Vazquez F, Bronson R, Rue M, et al: High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6: 263-274, 2004.
39. Oh A, List HJ, Reiter R, Mani A, Zhang Y, Gehan E, et al: The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Res 64: 8299-8308, 2004.
40. Osipo C, Meeke K, Liu H, Cheng D, Lim S, Weichel A, et al: Trastuzumab therapy for tamoxifen-stimulated endometrial cancer. Cancer Res 65: 8504-8513, 2005.
41. Santen R, Jeng MH, Wang JP, Song R, Masamura S, McPherson R, et al: Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 79: 115-125, 2001.
42. Lewis JS, Cheng D and Jordan VC: Targeting oestrogen to kill the cancer but not the patient. Br J Cancer 90: 944-949, 2004.
43. Osipo C, Liu H, Meeke K and Jordan VC: The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death. Exp Biol Med 229: 722-731, 2004.